Listed

DBV Technologies S.A.: Form 10-Q for the period ended Jun 30, 2025

Filed with the SEC on Jul 29, 2025 and accepted by EDGAR at Jul 29, 2025, 16:01 ET.

Share

Management's discussion and analysis

As filed, 37,229 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part 1, Item 1 of this Report and with our audited financial statements and related notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on April 11, 2025, as amended by Amendment No. 1 on Form 10-K/A filed with the SEC on April 28, 2025, and as amended further by Amendment No. 2 on Form 10-K/A filed with the SEC on May 14, 2025, or the Annual Report. This discussion and other parts of this Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause such differences are discussed in the section of this Report titled “Special Note Regarding Forward-Looking Statements” and under “Item 1A. Risk Factors” in the Annual Report.

Overview

We are a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. Our therapeutic approach is based on epicutaneous immunotherapy (EPIT) our proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). We have generated significant data demonstrating that Viaskin’s mechanism of action is novel and differentiated, Viaskin targets specialized antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen that accumulates in the outer layer of the skin, and then migrate to the skin-draining lymph nodes in order to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. We are advancing this unique technology to treat children suffering from food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. We believe Viaskin may offer convenient, self-administered, non-invasive immunotherapy to patients, if approved.

Our most advanced product candidate is the Viaskin Peanut patch, evaluated as a potential immunotherapy for children with peanut allergy in eleven clinical trials, including four Phase 2 trials and four completed Phase 3 trials. We are advancing two separate Viaskin Peanut product candidates in parallel to support two potential Biologics License Applications (BLAs) in two distinct age groups: one in toddlers ages one through three with the original (square) patch, and one in children ages four through seven with the modified (circular) patch.

Currently, we have an ongoing Phase 3 efficacy and safety trial (VITESSE) to evaluate the modified Viaskin Peanut patch in children ages four through seven with peanut allergy. On March 7, 2023, the Company announced that the first subject was screened in the VITESSE study. The Company announced on September 23, 2024 that subject screening was completed in the third quarter of 2024. Topline results are anticipated in the fourth quarter of 2025. On March 24, 2025, the Company announced that in a Written Responses Only to the Company’s Type D IND meeting request the FDA agreed with the Company’s proposal that the safety exposure data from the VITESSE Phase 3 study for Viaskin peanut patch in 4 – 7-year-olds will be sufficient to support a BLA filing in this age group. As a result, the COMFORT Children supplemental safety study will no longer be required and the Company will not conduct the study. The Company will utilize the safety data from the VITESSE subjects randomized to active treatment as well as placebo-crossover subjects in the VITESSE Open Label Extension (OLE). Accordingly, the Company plans to submit a BLA in the first half of 2026 and anticipates potentially accelerating the product launch by approximately one year, subject to FDA approval.

We also have an ongoing Phase 3 open-label extension to the EPITOPE trial (our completed Phase 3 efficacy and safety trial conducted in peanut-allergic toddlers which met its clinical endpoints), with 3-year results for active-treatment subjects in 2024, as well as a planned Phase 3 supplementary safety study, in peanut-allergic toddlers ages one through three. The Company submitted the protocol for its COMFORT Toddlers supplemental safety study in 1 – 3 years-old to the FDA on November 9, 2023. The Company received comments and queries to the protocol from the FDA on March 11, 2024.

On July 30, 2024, the Company announced that it and the FDA had been engaged in ongoing dialogue since May 2023 on the COMFORT Toddlers supplemental safety study in 1 – 3-years-old with a peanut allergy. The study protocol was submitted on November 9, 2023, with comments provided by FDA on March 11, 2024. After March, much of the dialogue between DBV and FDA regarding the COMFORT Toddlers supplemental study had focused on patch wear-time experience, including how prescribers would advise parents and caregivers to manage day-to-day variability in patch wear time. The Company proposed an approach, informed by the EPITOPE efficacy data, that focuses on the user experience during the first 90-days of treatment. The Company submitted to the FDA draft labeling for Section 2 – Dosing and Administration, for a potential Viaskin Peanut Prescribing Information (PI), along with comprehensive supportive data and analyses. Within the first 90-days of treatment (excluding the lead-in dosing period) it is possible to identify those patients who are very likely to have a robust clinical efficacy response based on patch wear time experience (i.e., “Label-in” patients). The proposed PI recommends continuation of treatment for these patients. With the same 90-day approach, patients less likely to have a robust clinical efficacy response, identified by their patch wear-time experience, would be identified as “Label-out” patients. In these instances, the PI would recommend a shared decision-making process, between the health care provider and the parent or caregiver, to determine whether treatment should be discontinued.

On October 22, 2024, the Company announced positive regulatory updates for the Viaskin Peanut patch in the United States and Europe. DBV agreed to guidance provided by the FDA on a potential pathway under the Accelerated Approval Program for the Viaskin Peanut patch in toddlers ages 1 – 3 years-old. FDA confirmed that the Company has met Accelerated Approval qualifying criterion 1 and 2 . Regarding criterion 3, FDA provided guidance and suggestion regarding the intermediate clinical endpoint, which the Company agreed to in informal discussions with the FDA. The Company formalized the Accelerated Approval guidance provided by FDA via submission of a meeting request and confirmed the general elements of the two study components: the COMFORT Toddlers safety study, to be completed before BLA submission, and the confirmatory effectiveness study, including the third Accelerated Approval criterion regarding the intermediate clinical endpoint. The Company expects that the confirmatory study will be initiated by the time of BLA submission and would run in parallel to commercialization in the United States, if the Viaskin Peanut patch is approved.

The Company announced further that it has aligned with FDA on a wear time collection methodology in COMFORT Toddlers that provides a practical approach for subjects and families, is intended to generate sufficient data to support a BLA submission, and places wear time into an acceptable clinical hierarchy relative to other study endpoints. DBV has initiated study start-up activities and plans to screen the first subject in the second quarter of 2025. The Company anticipates enrolling approximately 300 – 350 subjects on active treatment into the safety study, which would bring the total Viaskin

Peanut patch safety database in toddlers to approximately 600 subjects, consistent with prior FDA guidance. With this path forward, the BLA submission for Viaskin Peanut patch in 1 – 3 years-old under the Accelerated Approval program is anticipated to be supported by:

i. Positive efficacy and safety data from DBV’s previously completed EPITOPE Phase 3 Study; and

ii. Additional safety data generated in COMFORT Toddlers supplemental safety study, which was initiated in June quarter of 2025.

On December 11, 2024, the Company announced that it reached alignment with FDA on the Accelerated Approval pathway for Viaskin Peanut patch in toddlers 1-3 years-old and on key study design elements for the COMFORT Toddlers study, including study size and wear time collection methodology and analysis. The Company announced further that FDA confirmed criteria for a post-marketing confirmatory study in toddlers 1-3 years-old and that the Company and FDA agreed that the confirmatory study will assess the effectiveness of the intended commercial Viaskin Peanut patch, will include a include a double-blind, placebo-controlled food challenge (DBPCFC) and will use the same statistical criteria for success (i.e., lower bound of the 95% CI > 15%) as used in the EPITOPE and will need to be initiated at the time that the BLA is submitted.

On June 25, 2025, the Company announced that the first subject was screened in COMFORT Toddlers supplemental safety study in peanut allergic toddlers 1 – 3 years old.

The Company announced further that it sought scientific advice from the EMA regarding the components of a MAA for the Viaskin Peanut patch. Previous advice obtained from two local country regulatory health authorities indicated a potential path for a 1 – 7 year-old registration with one patch, the modified patch. The EMA recently confirmed through scientific advice that the completed EPITOPE study in 1 – 3 years-old, and a positive VITESSE study in 4 – 7 years-old, could constitute an MAA submission for a 1 – 7 year-old indication for peanut allergy patients using the modified patch, along with a new safety study in 1 – 3 years-old with the modified patch. Timing for the initiation of this new safety study to satisfy the important EU market is currently being planned.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The preparation of these unaudited condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the revenue, costs and expenses recognized during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no new policies or significant changes to our critical accounting policies as disclosed in the critical accounting policies described in the Annual Report. Our significant accounting policies are more fully described in Note 1 of the Notes to the Consolidated Financial Statements in Part I, Item 1 of our Annual Report.

Business Trends and Results of Operations

Comparison of the Three Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. dollars, for the three months ended June 30, 2025 and 2024.

2025 Three Months Ended June 30, 2024 $ change % of change
Operating income 1,465 1,161 303 26%
Operating expenses
Research and development expenses (33,693) (25,374) (8,319) 33%
Sales and marketing expenses (419) (986) 567 (58)%
General and administrative expenses (8,463) (8,643) 180 (2)%
Total Operating expenses (42,575) (35,003) (7,572) 22%
Financial income (expense) (648) 726 (1,374) (189)%
Income tax (117) — (117) —%
Net loss (41,875) (33,116) (8,759) 26%

Operating Income

The following table summarizes our operating income during the three months ended June 30, 2025 and 2024:

2025 Three Months Ended June 30, 2024 $ change % of change
Other income 1,465 1,161 303 26%
Research tax credit 1,465 1,161 303 26%
Total operating income 1,465 1,161 303 26%

Research tax credit increased by $0.3 million for the three months ended June 30, 2025, compared to the three months ended June 30, 2024 primarily due to a greater proportion of activities eligible to receive the Research tax credit carried out in the second quarter 2025 than in the second quarter 2024, and in particular with the launch of COMFORT Toddlers clinical trial.

Operating Expenses

Research and Development Expenses

The following table summarizes our research and development expenses incurred during the three months ended June 30, 2025 and 2024:

Research and Development expenses 2025 Three Months Ended June 30, 2024 $ change % of change
External clinical-related expenses 25,508 18,466 7,042 38%
Employee-related costs 5,153 4,481 672 15%
Share-based payment expenses 543 696 (153) (22)%
Depreciation, amortization and other costs 2,488 1,731 757 44%
Total Research and Development expenses 33,693 25,374 8,319 33%

Research and Development expenses increased by $8.3 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024.

External clinical-related expenses increased by $7.0 million mainly due to (1) the launch of the COMFORT Toddlers study following alignment with the FDA, (2) the progress of the VITESSE phase 3 clinical study, and (3) regulatory and production activities to support ongoing clinical trials.

Employee-related costs increased by $0.7 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024. This increase is due to (1) recruitments made during the second quarter of 2024, mainly based in the United States in Medical, Quality and Regulatory Affairs, for which a full quarter of personnel costs are recognized at end-June 2025, and (2) retroactive payment to January 1st of salary increases in the second quarter of 2025.

Depreciation, amortization and other costs increased by $0.8 million for the three months ended June 30, 2025 compared to the three months ended June 30, 2024. which comprised a favorable accrual reversal following the termination of the Collaboration Agreement with NESTEC,

Sales and Marketing Expenses

The following table summarizes our sales and marketing expenses incurred during the three months ended June 30, 2025 and 2024:

Sales & Marketing expenses 2025 Three Months Ended June 30, 2024 $ change % of change
External professional services 154 375 (100) (39)%
Employee-related costs 175 224 (171) (49)%
Share-based payment expenses 19 30 (10) (34)%
Depreciation, amortization and other costs 71 358 (287) (80)%
Total Sales & Marketing expenses 419 986 (567) (58)%

Sales and marketing expenses have decreased by $0.6 million during the three months ended June 30, 2025, compared to the three months ended June 30, 2024 mainly due to (1) lower Sales and Marketing activities, (2) lower sales headcount (down to 1 employee at the end of June 2024 compared with 2 employees for the same period of the previous year, following a transfer of assignment from sales to overheads) and (3) lower travel expenses.

General and Administrative Expenses

The following table summarizes our general and administrative expenses incurred during the three months ended June 30, 2025 and 2024:

General & Administrative expenses 2025 Three Months Ended June 30, 2024 $ change % of change
External professional services 2,552 3,162 (610) (19)%
Employee-related costs 3,225 2,614 611 23%
Share-based payment expenses 683 799 (116) (15)%

19

Depreciation, amortization and other costs 2,003 2,067 (64) (3)%
Total General & Administrative expenses 8,463 8,643 (180) (2)%

General and Administrative expenses decreased by $0.2 million for the three months ended June 30, 2025, compared to the three months ended June 30, 2024.

External professional services decreased by $0.6 million for the three months ended June 30, 2025, compared to the three months ended June 30, 2024 mainly due to (1) one-time costs associated with financing activities and (2) lower lease costs following office moves in France and the U.S.

Employee-related costs, excluding share-based payments, increased by $0.6 million for the three months ended June 30, 2025, compared to the three months ended June 30, 2024 due to (1) recruitments made during the second quarter of 2024 for which a full quarter of personnel costs are recognized at end-June 2025, and (2) retroactive payment to January 1st of salary increases in the second quarter of 2025 instead of the first quarter 2024.

Depreciation, amortization and other costs decreased by $0.1 million for the three months ended June 30, 2025, compared to the three months ended June 30, 2024 mainly due to (1) a lower lease cost in France and (2) a reduction in travel expenses.

Financial Income (Expense)

Our financial expense was $0.6 million for the three months ended June 30, 2025, compared to a financial income of $0.7 million for the three months ended June 30, 2024. This item mainly includes the financial income on our financial assets and foreign exchange result due to the appreciation of EUR vs USD in Q2 2025.

Income Tax

Our income tax expense was $117 thousands for the three months ended June 30, 2025 and was nil for the three months ended June 30, 2024.

Net Loss

Net loss was $41.9 million for the three months ended June 30, 2025, compared to $33.1 million for the three months ended June 30, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $ (0.31) and $ (0.34) for the three months ended June 30, 2025 and 2024, respectively.

Comparison of the Six Months Ended June 30, 2025 and 2024

The following table summarizes our results of operations, derived from our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP and presented in thousands of U.S. dollars, for the six months ended June 30, 2025 and 2024.

2025 Six Months Ended June 30, 2024 $ change % of change
Operating income 2,217 2,568 (351) (14)%
Operating expenses
Research and development expenses (55,176) (46,777) (8,399) 18%
Sales and marketing expenses (681) (1,744) 1,063 (61)%
General and administrative expenses (14,089) (16,447) 2,358 (14)%
Total Operating expenses (69,946) (64,968) (4,978) 8%
Financial income (expense) (1,109) 1,986 (3,095) (156)%
Income tax (117) (48) (69) 143%
Net loss (68,954) (60,461) (8,493) 14%

Operating Income

The following table summarizes our operating income during the six months ended June 30, 2025 and 2024:

2025 Six Months Ended June 30, 2024 $ change % of change
Other income 2,217 2,568 (351) (14)%
Research tax credit 2,217 2,568 (351) (14)%
Total operating income 2,217 2,568 (351) (14)%

During the six months ended June 30, 2025 we generated an Operating Income of $2.2.million compared to $2.6.million during the six months ended June 30, 2024.

Other operating income was nil for the six months ended June 30, 2025

Research tax credit decreased by $0.4 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024 primarily due to the fact that a greater proportion of clinical studies activities were carried out in North America and therefore not eligible for the French Research tax credit.

Operating Expenses

Research and Development Expenses

The following table summarizes our R&D expenses incurred during the six months ended June 30, 2025 and 2024:

Research and Development expenses 2025 Six Months Ended June 30, 2024 $ change % of change
External clinical-related expenses 39,466 32,492 6,974 21%
Employee-related costs 9,203 8,759 444 5%
Share-based payment expenses 1,124 1,466 (342) -23%
Depreciation, amortization and other costs 5,383 4,060 1,323 33%
Total Research and Development expenses 55,176 46,777 8,399 18.0%

Research and Development expenses increased by $8.4 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024.

External clinical-related expenses increased by $7.0 million mainly due to (1) the launch of the COMFORT Toddlers study following alignment with the FDA, (2) the progress of the VITESSE phase 3 clinical study, and (3) regulatory and production activities to support ongoing clinical trials.

Employee-related costs increased by $0.4 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. This increase is due to recruitments made during the second quarter of 2024, mainly based in the United States in Medical, Quality and Regulatory Affairs, for which six months of personnel costs are recognized at June 30, 2025 compared with two to three months at June 30, 2024.

Depreciation, amortization and other costs increased by $1.3 million for the six months ended June 30, 2025 compared to the six months ended June 30, 2024. This increase is mainly due to a $1.1 million provision reversal at June 30, 2024, following the termination of the Collaboration Agreement with NESTEC, which reduced last year's charge.

Sales and Marketing expenses

The following table summarizes our sales and marketing expenses incurred during the six months ended June 30, 2025 and 2024:

Sales & Marketing expenses 2025 Six Months Ended June 30, 2024 $ change % of change
External professional services 258 587 (329) -56.0%
Employee-related costs 312 506 (194) -38.3%
Share-based payment expenses 37 61 (24) -39.2%
Depreciation, amortization and other costs 72 589 (517) -87.7%
Total Sales & Marketing expenses 681 1,744 (1,063) -61.0%

Sales and Marketing expenses decreased by $1.1 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024, mainly due to (1) lower Sales and Marketing activities, (2) lower sales headcount (down to 1 employee at June 30, 2024 compared with 2 employees for the same period of the previous year, following a transfer of assignment from sales to overheads) and (3) lower travel expenses.

General and Administrative expenses

The following table summarizes our general and administrative expenses incurred during the six months ended June 30, 2025 and 2024:

General & Administrative expenses 2025 Six Months Ended June 30, 2024 $ change % of change
External professional services 3,604 5,595 (1,990) -35.6%
Employee-related costs 5,119 4,694 425 9.1%
Share-based payment expenses 1,786 1,956 (170) -8.7%
Depreciation, amortization and other costs 3,580 4,203 (622) -14.8%
Total General & Administrative expenses 14,089 16,447 (2,358) -14.3%

General and Administrative expenses decreased by $2.4 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024.

This decrease derives from decrease in external professional services due to non-recurring costs incurred in the first half of 2024 associated with (1) office relocations in France and the United States, (2) financing activities and (3) activities related to the Company's trademarks and patents.

Employee-related costs increased by $0.4 million for the six months ended June 30, 2025, compared to the six months ended June 30, 2024. This increase is mainly due to the recruitment carried out during the second quarter of 2024.

Depreciation, amortization and other costs decreased by $0.6 million mainly due to (1) the reduction in rent in France office following the move to new premises in Châtillon, (2) the reduction in insurance policies and (3) limited travel over the first half of 2025.

Financial income (expense)

Our financial expense was $1.1 million for the six months ended June 30, 2025, compared to a financial income of $2.0 million for the six months ended June 30, 2024. This item mainly includes financial income on our financial assets and a unfavorable foreign exchange result..

Income tax

Our income tax expense was $117 thousand for the six months ended June 30, 2025 compared to $48 thousand for the six months ended June 30, 2024.

Net loss

Net loss was $69.0 million for the six months ended June 30, 2025, compared to $60.5 million for the six months ended June 30, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $(0.58) and $(0.63) for the six months ended June 30, 2025 and 2024, respectively.

Liquidity and Capital Resources

Financial Condition

On June 30, 2025, we had $103.2 million in cash and cash equivalents compared to $32.5 million of cash and cash equivalents on December 31, 2024.

On March 27, 2025, the Company announced the 2025 financing (PIPE), as further described below, of up to $306.9 million (€284.5 million), to advance Viaskin® Peanut Patch through BLA submission and U.S. commercial launch, if approved.

On April 7, 2025, the Company received gross proceeds of $125.5 million (€116.3 million) from the issuance of securities including, ABSAs and PFW-BS-PFWs, as described in the Company’s Quarterly Report on Form 10-Q for the Quarter ended March 31, 2025 filed with the SEC on April 30, 2025.

With the receipt of the aforementioned proceeds, and based on its current operations, plans, and assumptions examined by the Board on June 23, 2025, the Company estimates that its cash and cash equivalents are sufficient to fund its operations into the second quarter of 2026. As such, there is substantial doubt regarding our ability to continue as a going concern.

The Company financing also includes an aggregate of up to $181.4 million (€168.2 million) in gross proceeds if all warrants are exercised, subject to satisfaction of specified conditions. The VITESSE Phase 3 study hitting its primary endpoint will trigger an acceleration of the exercise period of the warrants. DBV expects that the proceeds of this funding will be used for working capital and general corporate purposes, to finance the continued development of the Viaskin Peanut program, to finance the preparation and submission of a potential Biologics License Application (“BLA”) and, to finance the readiness of a launch of Viaskin peanut in the US, if approved.

Sources of Liquidity and Material Cash Requirements

On March 27, 2025, the Company entered into securities purchase agreements (together, the “Securities Purchase Agreements”) pursuant to which the Company agreed to issue and sell to various investors in a private placement (the “2025 PIPE”) the following securities:

  • a share capital increase without preferential subscription rights reserved to categories of persons satisfying determined characteristics pursuant to the 24th resolution of the general meeting of shareholders of May 16, 2024 (the "2024 General Meeting") completed on April 7, 2025 for an amount of €38 million, consisting of the issuance of (i) 34,090,004 new shares at a par value of €0.10 (the "New Shares") each with warrants of the Company attached (the "ABSA Warrants", and together with the New Shares, the "ABSA") at a subscription price of €1.1136 per ABSA and (ii) up to 59,657,507 additional new shares, if all the ABSA Warrants attached to the New Shares are exercised (the "ABSA Warrant Shares"); and
  • the issue through an offering reserved to categories of persons satisfying determined characteristics of 71,005,656 units (the “PFW-BS-PFW”) completed on April 7, 2025 for an amount of €79 million at a subscription price of €1.1136 per PFW-BS-PFW (of which €1.1036 will have been prefunded on the issue date), each PFW-BS-PFW consisting of one pre-funded warrant to subscribe for one share of the Company (the "First Pre-Funded Warrants") and one warrant (the "BS Warrants") to subscribe to one second pre-funded warrants (the "Second Pre-Funded Warrants"), each of which entitles the holder to subscribe for 1.75 shares of the Company (the "Second PFW Shares"), allowing to issue up to 71,005,656 additional new shares if all the First Pre-Funded Warrants are exercised (the "First PFW Shares") and up to 124,259,898 additional new shares if all the Second Pre-Funded Warrants are exercised (the "Second PFW Shares", together with the ABSA Warrant Shares and the First Pre-Funded Warrant Shares, the "Warrant Shares", and together with the New Shares, the "Offered Shares"). The Company has assessed the PFW-BS-PFW will be classified as a component of permanent equity

We have incurred net losses each year since our inception. Substantially all of our net losses resulted from costs incurred in connection with our development programs and from general and administrative expenses associated with our operations. We have not incurred any bank debt.

We may seek additional capital as we prepare for the launch of the Viaskin Peanut patch, if approved, and continue other research and development efforts. We may seek to finance our future cash needs through a combination of public or private equity or debt financings, collaborations, license and development agreements and other forms of non-dilutive financings.

We cannot guarantee that we will be able to obtain the necessary financing to meet our needs or to obtain funds at attractive terms and conditions, including as a result of disruptions to the global financial markets due any future pandemics, epidemics or global health crises and conflict in Ukraine or other global political or military crises. A severe or prolonged economic downturn could result in a variety of risks to us, including reduced ability to raise additional capital when needed or on acceptable terms, if at all. If we are not successful in our financing objectives, we could have to scale back our operations, notably by delaying or reducing the scope of our research and development efforts or obtain financing through arrangements with collaborators or others that may require us to relinquish rights to our product candidates that we might otherwise seek to develop or commercialize independently.

Operating Leases

Our corporate headquarters are located in Châtillon, France. Our principal offices occupy a 2,447 square meters facility, pursuant to a lease agreement dated November, 2023 and represents $6.8 million cash requirement as of June 30, 2025. The lease term ends in March, 2033.

Our primary U.S. office is located in Warren, New Jersey. In February 2024, we entered into a sublease agreement, commencing on March 19, 2024 and effective for 70 months, for an office of 16,704 square feet in Warren, New Jersey. The Warren office represent a $1.6 million cash requirement as of June 30, 2025 which expires December 31, 2029.

We also leased 5,799 square feet intended to support our U.S. operations in Basking Ridge, New Jersey, which commenced on April 1, 2022 and expired May 31, 2025. The Basking Ridge office represents a $26 thousand cash requirement as of June 30, 2025.

There have been no material changes in our operating leases from those disclosed in the Annual Report.

Purchase Obligations - Obligations Under the Terms of CRO Agreements

In preparation of the launch of our clinical trials for Viaskin Peanut, we signed agreements with several contract research organizations. As of June 30, 2025 expenses associated with the ongoing trials amounted globally to $272.7 million compared to $170.3 million as of December 31, 2024.

This increase is mainly due to the launch of the COMFORT Toddlers study following alignment with the FDA, and the progress of the VITESSE phase 3 clinical study.

Summary Statement of Cash Flows

The table below summarizes our sources and uses of cash for the six months ended June 30, 2025 and 2024.

(Amounts in thousands of U.S. Dollars)

Six Months Ended June 30, 2025 2024 $ change % of change
Net cash flow used in operating activities (53,573) (69,765) 16,192 (23)%
Net cash flow used in investing activities (413) (1,441) 1,027 (71)%
Net cash flow provided by (used in) financing activities 116,992 (95) 117,087 (123261)%
Effect of exchange rate changes on cash and cash equivalents 7,746 (3,853) 11,600 (301)%
Net (decrease) increase in cash and cash equivalents 70,752 (75,154) 145,906 (194)%

Operating Activities

Our net cash flows used in operating activities were $53.6 million and $69.8 million during the six months ended June 30, 2025 and 2024, respectively. Our net cash flows used in operating activities decreased by $16.2 million as our costs and expenses have been contained and payment terms extended during the Company’s financing period.

The decrease compared to last year is mainly due to (1) the reduction of external expenses related to completed or expiring clinical trials for $3.4 million, (2) the deferral of Research & Development activities to support clinical trial progress through regulatory affairs, medical affairs, the manufacturing platform and procurement activities for $5.1 million, and (3) deferrals of Sales & Marketing activities, travel expenses and savings on insurance policies.

Investing Activities

Our net cash flows used in investing activities were $0.4 million and $1.4 million during the six months ended June 30, 2025 and 2024 respectively. The variance is primarily explained by capitalized costs for the headquarters move to Châtillon.

Financing Activities

Our net cash flows from financing activities were $117.0 million for the six months ended June 30, 2025 compared to $(95) thousand for the six months ended June 30, 2024. This increase is due to the financing operation completed on April 7, 2025.

Off-Balance Sheet Arrangements

We have not entered into any off-balance sheet arrangements and do not have variable interests in variable interest entities.

Smaller Reporting Company Status

We are a smaller reporting company as defined in the Securities Exchange Act of 1934, as amended. We may, and intend to, take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as we are a smaller reporting company. We may be a smaller reporting company in any year in which (i) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter or (ii) (a) our annual revenue is less than $100.0 million during the most recently completed fiscal year and (b) the market value of our voting and non-voting ordinary shares held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

Market risk

As filed, 153 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Controls and procedures

As filed, 2,830 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

Based on its evaluation as of June 30, 2025, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) were effective to provide reasonable assurance that (i) the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitation on Effectiveness of Controls and Procedures

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies and procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error of fraud may occur and not be detected.

Risk factors

As filed, 683 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and trading price of our securities. In addition to the other information set forth in this Quarterly Report, you should carefully consider the factors described in Part I, Item 1A. “Risk Factors” of our Annual Report. As of June 30, 2025, substantial doubt exists about our ability to continue as a going concern due to ongoing operating losses and liquidity challenges. While management has plans to address these issues, there is no assurance these plans will be successful, which could materially impact our business and financial condition.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2025-04-01 to 2025-06-30$1.5mus-gaap:Revenues
Revenue6 months2025-01-01 to 2025-06-30$2.2mus-gaap:Revenues
Research and development3 months2025-04-01 to 2025-06-30$33.7mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2025-01-01 to 2025-06-30$55.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2025-04-01 to 2025-06-30−$41.1mus-gaap:OperatingIncomeLoss
Operating income6 months2025-01-01 to 2025-06-30−$67.7mus-gaap:OperatingIncomeLoss
Income tax3 months2025-04-01 to 2025-06-30$117.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2025-01-01 to 2025-06-30$117.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2025-04-01 to 2025-06-30−$41.9mus-gaap:NetIncomeLoss
Net income6 months2025-01-01 to 2025-06-30−$69.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2025-04-01 to 2025-06-30−$0.31us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2025-01-01 to 2025-06-30−$0.58us-gaap:EarningsPerShareDiluted
Basic EPS3 months2025-04-01 to 2025-06-30−$0.31us-gaap:EarningsPerShareBasic
Basic EPS6 months2025-01-01 to 2025-06-30−$0.58us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2025-04-01 to 2025-06-30134,476,503 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2025-01-01 to 2025-06-30118,545,638 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2025-01-01 to 2025-06-30−$53.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2025-01-01 to 2025-06-30$42.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2025-06-30$103.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2025-06-30$121.2mus-gaap:AssetsCurrent
Total assetsAt period end2025-06-30$143.4mus-gaap:Assets
Current liabilitiesAt period end2025-06-30$49.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2025-06-30$57.2mus-gaap:Liabilities
Shareholders' equityAt period end2025-06-30$86.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001613780-25-000016. Last ingested by Listed: Nov 14, 2026, 12:53 ET. Listed shows no prices and gives no investment advice.